My bookmarksSign up free

2002/953/EC: Commission Decision of 5 December 2002 on a… Article 1

Article 1

The Funds contained in Trust Fund 911100/MTF/INT/003/EEC, provided for in Decision 2001/300/EC, shall be used for the following measures: (a) the purchase of 1000000 doses of Al(OH)3-adjuvated trivalent vaccine against the foot-and-mouth disease virus of types O1, A-Iran 96 and ASIA1 with a potency of 6 PD50; (b) the delivery of the doses of the vaccine referred to in point (a) to the central veterinary authorities of Armenia, Azerbaijan and Georgia for emergency vaccination in the districts along their southern borders of susceptible animals in accordance with the vaccination programme to be set up by letter of agreement between the veterinary authorities of those countries and the European Commission for the Control of Foot-and-Mouth Disease (EUFMD); (c) on-the-spot supervision of the vaccination campaign and organisation of a serological surveillance by an expert appointed by EUFMD; (d) the supply of test kits for the detection of antibodies against non-structural proteins, the monitoring of the vaccination campaign and the substantiation of the disease situation.

Read the full instrument →

Other provisions in 2002/953/EC: Commission Decision of 5 December 2002 on a…

Compiled from an official source version. Later amendments or repeals may not be reflected; the official text prevails. · Read the official text ↗ · Data as of 2026-07-04

CitationArticle 1 of 2002/953/EC: Commission Decision of 5 December 2002 on a… (LawPlayer, data as of 2026-07-04)

© European Union, https://eur-lex.europa.eu, 1998-2026. Reuse authorised under Commission Decision 2011/833/EU, provided the source is acknowledged.

What to look at next